Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted inhaled medicines for severe respiratory conditions. The company's pipeline is primarily focused on treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Its lead product candidates, AP01 and AP02, are inhaled formulations of the established anti-fibrotic small-molecule drugs pirfenidone and nintedanib. These therapies are designed to improve efficacy and reduce systemic side effects by delivering medication directly to the lungs. Additionally, Avalyn is advancing AP03, a fixed-dose combination of both drugs. Operating from its headquarters in Boston, the company aims to establish a new standard of care for patients with rare lung diseases.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!